COR · Q3 2026 Earnings

Neutral

Cencora

Reported August 5, 2026

30-second summary

SENTIMENT: Constructive 30-second take: Cencora printed Q3 revenue of $84.8B (+5.1% YoY) and adjusted EPS of $4.48 (+12.0%), with U.S. Healthcare Solutions revenue +4.9% and segment operating income of $966.2M (+15.9% YoY) — a sharp reacceleration from Q2's soft print that lands comfortably inside the updated 14.5–15.5% FY U.S. OI growth guide. Management raised FY26 adjusted EPS guidance $0.05 at the midpoint to $17.75–$17.95 (from the current PR's stated prior range of $17.70–$17.90), tightened consolidated OI growth to 13–14%, narrowed U.S. OI growth to 14.5–15.5%, raised International OI growth to ~9% (from 5–8%) while trimming International revenue growth to ~8% (from 8–10%), raised Other revenue growth to ~6% and Other OI growth to ~10%, and executed $1B of buybacks in the quarter. The International story is not a simple cut: revenue guide trimmed, but OI guide meaningfully raised on European distribution and specialty logistics strength. The EPS raise is real and buyback-supported; the U.S. OI reacceleration and the raised segment OI framework validate the FY trajectory management laid out earlier in the year.

Headline numbers

EPS

Q3 FY2026

$4.48

Revenue

Q3 FY2026

$84.80B

+5.1% YoY

Gross margin

Q3 FY2026

4.3%

Operating margin

Q3 FY2026

1.3%

Key financials

Q3 FY2026

Metric	Q3 FY2026	Q3 FY2025	YoY	Q2 FY2026	QoQ
Revenue	$84.80B	$80.70B	+5.1%	$78.40B	+8.2%
EPS	$4.48	$4.00	+12.0%	$4.75	-5.7%
Gross margin	4.3%	3.6%	+66bps	4.3%	-5bps
Operating margin	1.3%	1.1%	+24bps	1.6%	-29bps

Guidance

Company raises full-year FY2026 EPS guidance to $17.75–$17.95 and tightens operating income growth while lowering International segment growth expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted diluted EPS	FY 2026	$17.65 to $17.90	$17.75 to $17.95	+$0.10 at midpoint (low end +$0.10, high end +$0.05)	Raised
International Healthcare Solutions Segment revenue growth	FY 2026	8% to 10% growth	~8% growth	-2pts (high end lowered from 10% to 8%)	Lowered
Other segment revenue growth	FY 2026	1% to 5% growth	~6% growth	+1pt (high end raised from 5% to 6%)	Raised
Adjusted operating income growth	FY 2026	12% to 14% growth	13% to 14% growth	+1pt (low end raised from 12% to 13%)	Raised
Net interest expense	FY 2026	~$485M	~$490M	+$5M	Raised
Diluted weighted average shares outstanding	FY 2026	Under 195.5M	~194M	-1.5M shares (share count reduced by ~1.5M)	Lowered

Segment KPIs

Q3 FY2026

Segment	Q3 FY2026	Q3 FY2025	YoY
U.S. Healthcare Solutions	$74.9B	$72.9B	+2.7%
International Healthcare Solutions	$7.7B	$7.8B	-1.3%
Other	$2.3B	—	+6.9%
U.S. Healthcare Solutions Operating Income	$966.2M	—	—
International Healthcare Solutions Operating Income	$165.9M	—	—
Other Operating Income	$108.7M	—	—

Other KPIs

Q3 FY2026

Segment	Q3 FY2026	Q3 FY2025	YoY
Adjusted Operating Margin	1.46%	—	—
Adjusted Gross Profit Margin	4.16%	3.55%	—
Share Repurchases Q3	$1.0B	—	—
Specialty Products Growth	Increased sales to health systems and physician practices	—	—
GLP-1 Products	Increased sales of diabetes and weight loss products	—	—

Management tone

Customer optimization hangover → U.S. specialty acceleration → Portfolio pruning and capacity commitment → Transitory headwinds and defensive reframing → Operational reacceleration with segment framework intact.

No transcript available for this quarter — tone analysis is limited to press-release commentary and disclosure changes vs prior quarters.

Last quarter management leaned on "transitory" framing to bridge a 5.6% U.S. OI print against a reaffirmed 14–16% FY target. This quarter, the U.S. OI print reaccelerated to +15.9% and the segment guide was narrowed to 14.5–15.5% — the "transitory" characterization now has empirical support rather than being an assertion. Anchor from the press release: "Our strong performance and confidence in our outlook enabled us to raise our fiscal 2026 guidance." The confidence shows up in the numbers: EPS raised, consolidated OI raised at the low end, U.S. OI narrowed with the print at the top of the range, International OI raised meaningfully, Other raised on both lines.

The buyback pace signals a valuation-driven capital allocation posture layered on top of operational strength. A quarter ago management committed to $1B of repurchases through end of calendar 2026 — a ~15-month runway. They executed the entire $1B in Q3. Combined with the share count guide moving from "Under 195.5M" to "~194M," Cencora front-loaded the buyback into the quarter where operating results also accelerated. The mechanical EPS support is real, but the operational EPS support is also real — adjusted EPS grew 12.0% on ~0.7% lower share count, so the majority of the EPS growth is coming from operations, not buybacks.

The structural growth narrative — "specialty, digital transformation and talent" — remains verbatim quarter-to-quarter: "Our investments in specialty, digital transformation and talent are strengthening our ability to support our customers." The language hasn't evolved, but with U.S. OI +15.9%, International OI +20.8%, and Other OI +24.8%, the language is now doing less analytical work than the numbers are.

Answers to last quarter's watch list

Q3 FY26 U.S. HC Solutions OI growth — Q2 printed 5.6% against a 14–16% reaffirmed FY range; Q3 needs to be meaningfully closer to ~15% to keep the FY guide credible. Resolved positively. Q3 U.S. HC Solutions OI grew 15.9% YoY ($966.2M vs. $833.7M), landing at the top of the prior 14–16% range and above the midpoint of the new 14.5–15.5% guide. The Q2 "transitory" framing is now supported by a genuine sequential reacceleration.

Resolved positively

Q3 FY26 revenue against the new 4–6% FY guide — Q2 printed at +3.8%, below the low end. Resolved positively. Q3 revenue grew 5.1% YoY, inside the 4–6% FY range and above Q2's +3.8%. U.S. HC Solutions revenue accelerated from +2.9% in Q2 to +4.9% in Q3.

Resolved positively

Pace of the $1B buyback through fiscal Q3 and Q4. Resolved. Management executed the entire $1B commitment in Q3 alone — an aggressive front-load that tightened the share count guide to ~194M and mechanically supports the EPS raise.

Resolved positively

First evidence of mail-order pharmacy brand conversion stabilization. The company didn't explicitly quantify. The Q3 press release notes lower sales to the large mail order customer continued "as expected and consistent with our second quarter," while the 210bps sequential improvement in U.S. HC Solutions revenue growth (2.9% → 4.9%) is consistent with brand conversions no longer accelerating as a headwind.

Continue monitoring

First announced divestiture transaction from MWI, U.S. hub services, Profarma, or PharmaLex. U.S. Consulting Services was divested in April 2026. Other transactions from the strategic alternatives review have not yet been announced. The Other segment continues to outperform (revenue +6.9%, OI +24.8%, MWI called out as a growth driver), which is a live tension with the portfolio-refocus narrative. Balance-sheet-wise, $3.8B of assets and $0.9B of liabilities are now classified as held for sale, suggesting transactions may be closer than they appear. Status: Partially resolved (U.S. Consulting Services); continue monitoring.

What to watch into next quarter

Q4 FY26 revenue against the 4–6% FY guide — Q3 delivered +5.1% and the FY YTD sits at +4.8%; Q4 needs to hold in the mid-single-digit range to land the FY inside the guide.

International HC Solutions revenue actually printing ~8% YoY in Q4 — Q3 came in at +5.9% against a ~8% FY guide, meaning Q4 needs to accelerate meaningfully or the revenue guide gets cut a third time. The OI side is running well ahead of guide, so a revenue miss with an OI beat remains a plausible outcome.

Any capital allocation refresh — second buyback authorization or M&A signal — the $1B commitment is now spent. Management's next disclosure on repurchases or acquisition activity will reveal whether the aggressive Q3 pace was a one-time confidence signal or the start of a more assertive posture.

Progress on held-for-sale assets — with $3.8B of assets and $0.9B of liabilities classified as held for sale on the June 30 balance sheet, the next quarter should bring more concrete transaction activity beyond the U.S. Consulting Services divestiture.

FY27 initial guidance framing on U.S. HC Solutions OI growth — the oncology customer headwind fully laps in Q4 FY26 and the RCA / OneOncology comp base normalizes. Whether management guides U.S. OI in the mid-teens again or resets to a lower range will reveal how much of the FY26 strength they view as durable versus acquisition-driven.

Sources

Cencora Q3 FY2026 press release (Exhibit 99.1, filed 2026-08-05): https://www.sec.gov/Archives/edgar/data/1140859/000114085926000032/exhibit991-q32026.htm
Cencora Q2 FY2026 brief (Tapebrief, 2026-05-06) for prior-guide reference points
Cencora Q1 FY2026 brief (Tapebrief, 2026-02-04) for multi-quarter U.S. OI trajectory
Cencora Q4 FY2025 brief (Tapebrief, 2025-11-05) for FY26 initial guide baseline
Cencora Q3 FY2025 brief (Tapebrief, 2025-08-06) for prior-year comparison base

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.